HealthAI imageGSK to Acquire Promising T Cell-Engager for Multiple Myeloma
GSK plc announced an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a private biotechnology company. This acquisition aims to advance GSK's portfolio in immuno-oncology, specifically targeting multiple myeloma, a type of blood cancer. The deal highlights GSK's commitment to developing innovative cancer therapies.
Pharma Biz·


